APELLIS PHARMACEUTICALS STOCK RISES 3.8% FOLLOWING BOFA GLOBAL RESEARCH UPGRADE TO BUY FROM NEUTRAL
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: moomoo
Stock Performance: Apellis Pharmaceuticals shares have decreased by 3.8%.
Research Upgrade: A global research firm has upgraded its rating on Apellis Pharmaceuticals to "Buy".
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
